Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: A nerve conduction study

C. Butera, R. Guerriero, S. Amadio, D. Ungaro, H. Tesfaghebriel, F. Bianchi, G. Comi, U. Del Carro

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Botulinum toxin type-A is currently thought to be effective and safe for hemifacial spasm (HFS). The pre-synaptic block of acetylcholine release at the neuromuscular junction induces depression of orbicularis oculi muscle compound motor action potential (CMAP). The aim of our study was to evaluate at what extent end-plate functional recovery is possible even in botulinum toxin treatments lasting up to 15 years. We examined 81 outpatients with primary HFS (mean treatment duration = 7.2 ± 4.2 years) who underwent neurophysiologic study, once clinical effect of the previous treatment had vanished. The mean CMAP amplitude, mean rectified amplitude of response 1 (R1) of the blink reflex and area of response 2 (R2) of treated orbicularis oculi muscle were measured in comparison to the controlateral side. Mean amplitude of the above mentioned parameters was slightly lower (about 20%; p <0.001) in the treated side at the end of the follow-up period (4.7 ± 1.7 months). The CMAP amplitude reduction weakly correlated with the interval from last treatment, while other neurophysiologic parameters did not change due to treatment duration or total toxin amount. Our study demonstrates that botulinum toxin affects compound motor action potential and blink-reflex responses for at least 4-5 months in HFS patients. The residual block is slight and does not increase with repeated injections after several years of treatment. Our study, beside confirming the long-term efficacy of botulinum toxin treatment for HFS, provides neurophysiologic evidence that therapeutic effect may be obtained without hindering the regenerative potential of the nerve-muscle complex.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalNeurological Sciences
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Hemifacial Spasm
Botulinum Toxins
Neural Conduction
Action Potentials
Blinking
Muscles
Therapeutics
Delayed Emergence from Anesthesia
Type A Botulinum Toxins
Neuromuscular Junction
Therapeutic Uses
Acetylcholine
Outpatients
Injections

Keywords

  • All movement disorders
  • Botulinum toxin
  • CMAP
  • EMG
  • Hemifacial spasm

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm : A nerve conduction study. / Butera, C.; Guerriero, R.; Amadio, S.; Ungaro, D.; Tesfaghebriel, H.; Bianchi, F.; Comi, G.; Del Carro, U.

In: Neurological Sciences, Vol. 34, No. 2, 02.2013, p. 209-215.

Research output: Contribution to journalArticle

Butera, C. ; Guerriero, R. ; Amadio, S. ; Ungaro, D. ; Tesfaghebriel, H. ; Bianchi, F. ; Comi, G. ; Del Carro, U. / Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm : A nerve conduction study. In: Neurological Sciences. 2013 ; Vol. 34, No. 2. pp. 209-215.
@article{37d031afa31c4d6cb5511ef1ac319b33,
title = "Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: A nerve conduction study",
abstract = "Botulinum toxin type-A is currently thought to be effective and safe for hemifacial spasm (HFS). The pre-synaptic block of acetylcholine release at the neuromuscular junction induces depression of orbicularis oculi muscle compound motor action potential (CMAP). The aim of our study was to evaluate at what extent end-plate functional recovery is possible even in botulinum toxin treatments lasting up to 15 years. We examined 81 outpatients with primary HFS (mean treatment duration = 7.2 ± 4.2 years) who underwent neurophysiologic study, once clinical effect of the previous treatment had vanished. The mean CMAP amplitude, mean rectified amplitude of response 1 (R1) of the blink reflex and area of response 2 (R2) of treated orbicularis oculi muscle were measured in comparison to the controlateral side. Mean amplitude of the above mentioned parameters was slightly lower (about 20{\%}; p <0.001) in the treated side at the end of the follow-up period (4.7 ± 1.7 months). The CMAP amplitude reduction weakly correlated with the interval from last treatment, while other neurophysiologic parameters did not change due to treatment duration or total toxin amount. Our study demonstrates that botulinum toxin affects compound motor action potential and blink-reflex responses for at least 4-5 months in HFS patients. The residual block is slight and does not increase with repeated injections after several years of treatment. Our study, beside confirming the long-term efficacy of botulinum toxin treatment for HFS, provides neurophysiologic evidence that therapeutic effect may be obtained without hindering the regenerative potential of the nerve-muscle complex.",
keywords = "All movement disorders, Botulinum toxin, CMAP, EMG, Hemifacial spasm",
author = "C. Butera and R. Guerriero and S. Amadio and D. Ungaro and H. Tesfaghebriel and F. Bianchi and G. Comi and {Del Carro}, U.",
year = "2013",
month = "2",
doi = "10.1007/s10072-012-0987-z",
language = "English",
volume = "34",
pages = "209--215",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm

T2 - A nerve conduction study

AU - Butera, C.

AU - Guerriero, R.

AU - Amadio, S.

AU - Ungaro, D.

AU - Tesfaghebriel, H.

AU - Bianchi, F.

AU - Comi, G.

AU - Del Carro, U.

PY - 2013/2

Y1 - 2013/2

N2 - Botulinum toxin type-A is currently thought to be effective and safe for hemifacial spasm (HFS). The pre-synaptic block of acetylcholine release at the neuromuscular junction induces depression of orbicularis oculi muscle compound motor action potential (CMAP). The aim of our study was to evaluate at what extent end-plate functional recovery is possible even in botulinum toxin treatments lasting up to 15 years. We examined 81 outpatients with primary HFS (mean treatment duration = 7.2 ± 4.2 years) who underwent neurophysiologic study, once clinical effect of the previous treatment had vanished. The mean CMAP amplitude, mean rectified amplitude of response 1 (R1) of the blink reflex and area of response 2 (R2) of treated orbicularis oculi muscle were measured in comparison to the controlateral side. Mean amplitude of the above mentioned parameters was slightly lower (about 20%; p <0.001) in the treated side at the end of the follow-up period (4.7 ± 1.7 months). The CMAP amplitude reduction weakly correlated with the interval from last treatment, while other neurophysiologic parameters did not change due to treatment duration or total toxin amount. Our study demonstrates that botulinum toxin affects compound motor action potential and blink-reflex responses for at least 4-5 months in HFS patients. The residual block is slight and does not increase with repeated injections after several years of treatment. Our study, beside confirming the long-term efficacy of botulinum toxin treatment for HFS, provides neurophysiologic evidence that therapeutic effect may be obtained without hindering the regenerative potential of the nerve-muscle complex.

AB - Botulinum toxin type-A is currently thought to be effective and safe for hemifacial spasm (HFS). The pre-synaptic block of acetylcholine release at the neuromuscular junction induces depression of orbicularis oculi muscle compound motor action potential (CMAP). The aim of our study was to evaluate at what extent end-plate functional recovery is possible even in botulinum toxin treatments lasting up to 15 years. We examined 81 outpatients with primary HFS (mean treatment duration = 7.2 ± 4.2 years) who underwent neurophysiologic study, once clinical effect of the previous treatment had vanished. The mean CMAP amplitude, mean rectified amplitude of response 1 (R1) of the blink reflex and area of response 2 (R2) of treated orbicularis oculi muscle were measured in comparison to the controlateral side. Mean amplitude of the above mentioned parameters was slightly lower (about 20%; p <0.001) in the treated side at the end of the follow-up period (4.7 ± 1.7 months). The CMAP amplitude reduction weakly correlated with the interval from last treatment, while other neurophysiologic parameters did not change due to treatment duration or total toxin amount. Our study demonstrates that botulinum toxin affects compound motor action potential and blink-reflex responses for at least 4-5 months in HFS patients. The residual block is slight and does not increase with repeated injections after several years of treatment. Our study, beside confirming the long-term efficacy of botulinum toxin treatment for HFS, provides neurophysiologic evidence that therapeutic effect may be obtained without hindering the regenerative potential of the nerve-muscle complex.

KW - All movement disorders

KW - Botulinum toxin

KW - CMAP

KW - EMG

KW - Hemifacial spasm

UR - http://www.scopus.com/inward/record.url?scp=84879691639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879691639&partnerID=8YFLogxK

U2 - 10.1007/s10072-012-0987-z

DO - 10.1007/s10072-012-0987-z

M3 - Article

C2 - 22367224

AN - SCOPUS:84879691639

VL - 34

SP - 209

EP - 215

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 2

ER -